Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
暂无分享,去创建一个
D. Takahari | H. Osumi | K. Yamaguchi | T. Wakatsuki | M. Ozaka | E. Shinozaki | M. Ogura | M. Suenaga | A. Ooki | I. Nakayama | D. Kamiimabeppu | Taro Sato | Takeshi Suzuki | K. Chin
[1] Y. Todo,et al. Diagnostic criteria of sentinel lymph node micrometastasis or macrometastasis based on tissue rinse liquid-based cytology in gynecological cancer , 2020, International Journal of Clinical Oncology.
[2] S. Kalnicki,et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.
[3] Amit N. Patel,et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.
[4] A. Khorana,et al. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. , 2020, JCO oncology practice.
[5] Xiang Chen,et al. Clinical determinants for fatality of 44,672 patients with COVID-19 , 2020, Critical Care.
[6] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[7] Jian Chen,et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.
[8] Nils Kucher,et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.
[9] H. Miyashita,et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.
[10] E. Basch,et al. Oncology Practice During the COVID-19 Pandemic. , 2020, JAMA.
[11] Bolin Wang,et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis , 2020, Aging.
[12] C. Pinto,et al. Indications regarding the management of interventional clinical trials with drugs during the current COVID-19 emergency in Italy , 2020, ESMO Open.
[13] A. Kishan,et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 , 2020, Advances in Radiation Oncology.
[14] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[15] A. Ravaud,et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection , 2020, The Lancet Oncology.
[16] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[17] R. Trimble. COVID-19 Dashboard , 2020 .
[18] Huahao Shen,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[19] Huahao Shen,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[20] Li Zhang,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[21] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[22] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[23] Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.
[24] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[25] Masahiro Yoshida,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.
[26] Y. Kodera,et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Ajani,et al. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma , 2019, Oncology.
[28] T. Fujii,et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.
[29] G. Honda,et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.
[30] Kazuhiro Yoshida,et al. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) , 2018, Gastric Cancer.
[31] G. Beretta,et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[32] Masahiro Yoshida,et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 , 2018, Esophagus.
[33] D. Zylis,et al. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. , 2018, In vivo.
[34] J. Meyerhardt,et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[35] R. Labianca,et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.
[36] E. Oki,et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. , 2018, European journal of cancer.
[37] J. Tabernero,et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] K. Akashi,et al. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer , 2018, Gastric Cancer.
[39] T. Matsushima,et al. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma , 2018, International Journal of Clinical Oncology.
[40] M. Shah,et al. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm , 2017, Gastric Cancer.
[41] K. Muro,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[43] T. Bekaii-Saab,et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis , 2017, Therapeutic advances in medical oncology.
[44] Masahiro Yoshida,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.
[45] K. Chìn,et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer , 2016, British Journal of Cancer.
[46] N. Sata,et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.
[47] A. Klein,et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma , 2015, Cancer Chemotherapy and Pharmacology.
[48] T. Kawano,et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) , 2015, Cancer science.
[49] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[50] A. Nashimoto,et al. Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis , 2014, The British journal of surgery.
[51] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[52] K. Bujko,et al. Neoadjuvant radiotherapy (5 × 5 Gy): immediate versus delayed surgery. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[53] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[54] Y. Ohashi,et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Y. Yatabe,et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. , 2011, Anticancer research.
[56] M. Shinoda,et al. A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) , 2011, Annals of Surgical Oncology.
[57] O. Yokosuka,et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer , 2011, Cancer Chemotherapy and Pharmacology.
[58] N. Boku,et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. , 2010, Japanese journal of clinical oncology.
[59] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[60] A. Sato,et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). , 2009, Japanese journal of clinical oncology.
[61] B. Uzzan,et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.
[62] Anthony S Fauci,et al. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.
[63] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[64] H. Yamana,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] William E. Patrick. The Food and Drug Administration , 1988 .